Compare Inovio Pharmaceuticals Inc (INO) vs PepsiCo, Inc. (PEP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs PepsiCo, Inc. — how do they compare? Inovio Pharmaceuticals Inc trades at $1.09 (market cap $89.27M), while PepsiCo, Inc. trades at $134.58 (market cap $184.89B). The key difference: PepsiCo, Inc. is far larger — about 2071.1× Inovio Pharmaceuticals Inc's market cap, and PepsiCo, Inc. pays a 4.37% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INO | PEP | |
|---|---|---|
Market Cap | $89.27M | $184.89B |
Sector | Health | Consumer Staples |
52-Week High | $2.87 | $170.44 |
52-Week Low | $1.05 | $135.40 |
Enterprise Value | $60.28M | $227.39B |
Dividend Yield | — | 4.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.
Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.
PepsiCo (PEP) trades at $134.62, down 1.82% over the past day, with a bearish technical signal from moving averages. The company reported revenue of $93.93B in 2025, with a net income margin of 10.78% and a P/E ratio of 17.75. Recent news highlights price cuts on snacks like Doritos to address consumer pushback, while Q3 2026 earnings are anticipated at $2.32 EPS. Analyst consensus is a 'Hold' with a $158.50 price target, suggesting moderate upside from current levels.
The outlook for PEP hinges on execution of its North American turnaround and margin expansion initiatives. Risks include competitive pressures and sensitivity to consumer spending. With strong cash flow generation and a dividend yield near 4%, the stock offers value for income-focused investors, though near-term volatility may persist amid earnings uncertainty and market sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About PepsiCo, Inc.
PepsiCo is one of the largest food and beverage companies globally. It makes, markets, and sells a slew of brands across the beverage and snack categories, including Pepsi, Mountain Dew, Gatorade, Doritos, Lays, and Ruffles. The firm uses a largely integrated go-to-market model, though it does leverage third-party bottlers, contract manufacturers, and distributors in certain markets. In addition to company-owned trademarks, Pepsi manufactures and distributes other brands through partnerships and joint ventures with companies such as Starbucks. The firm segments its operations into five primary geographies, with North America (comprising Frito-Lay North America, Quaker Foods North America, and North America beverages) constituting around 60% of consolidated revenue.
Read more on PEP →
